|
 |
 |
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
||||
 David MottChairman of the Board General Partner, New Enterprise Associates, Inc. Mr. Mott joined New Enterprise Associates, Inc. (NEA) in September 2008 as a General Partner focused on biopharmaceutical investments. Prior to joining NEA, he was President and Chief Executive Officer of MedImmune, subsidiary of AstraZeneca Plc, and Executive Vice President of AstraZeneca. Mr. Mott joined MedImmune in 1992 and served in roles of increasing responsibility including Chief Operating Officer, Chief Financial Officer, President and Chief Executive Officer as the company grew from a venture-backed startup (founded in 1988) into one of the top five biotechnology companies in the world. Ultimately, he initiated and executed the sale of MedImmune to AstraZeneca in June 2007 for $15.6 billion. In 2002, Mr. Mott founded MedImmune Ventures and chaired its investment committee through his departure from MedImmune. At the time of his departure in July 2008, MedImmune had annual revenues in excess of $1.5 billion, annual R&D in excess of $650 million and more than 3,000 employees. Prior to joining MedImmune, Mr. Mott was a Vice President in the Health Care Investment Banking Group at Smith Barney, Harris Upham & Co. Inc. At Smith Barney, his activities included public and private equity and debt financings as well as merger and acquisition work for biotechnology, healthcare services, and medical product and device companies. Mr. Mott is currently a director of Ardelyx, Rib-x Pharmaceuticals, Shire plc (NASDAQ: SHPGY) and Zosano Pharma, and serves on the Advisory Board of the Scripps Translational Science Institute. He is also a member of the St. Albans School Governing Board. Mr. Mott is a former board member of Ambit Biosciences, Conceptis Technologies, and MedImmune, Inc. and has served on numerous industry trade group and not-for-profit boards, including the Biotechnology Industry Organization (BIO) and the High Tech Council of Maryland. He holds a bachelor’s degree in economics and government from Dartmouth College. |
© 2009 3-V Biosciences, Inc. |